Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis

Anna Alisi*, Sara Ceccarelli, Nadia Panera and Valerio Nobili

Liver Research Unit and Hepato-Metabolic Disease Unit, “Bambino Gesù” Children’s Hospital, IRCCS, Rome, Italy

*Correspondence: anna.alisi@opbg.net

Edited by:
Lorenza Putignani, Children’s Hospital and Research Institute Bambino Gesù, Italy

Reviewed by:
Lorenza Putignani, Children’s Hospital and Research Institute Bambino Gesù, Italy
Andrea Petrucca, Azienda Ospedaliera Sant’Andrea, Italy

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide (Milić and Stimac, 2012). NAFLD affects prevalently children and adults with particular risk factors including genetic susceptibility and inappropriate lifestyle (i.e., over-/mal-nutrition and physical inactivity). In fact, obesity, as well as some traits of metabolic syndrome, such as insulin resistance and dyslipidemia, are co-morbidities often associated to the presence of NAFLD (Vanni et al., 2010). In line with the increased obesity epidemics, epidemiological studies indicate that the estimated global prevalence of NAFLD ranges from 3–10% depending on age, sex, ethnicity, and risk factors. Interestingly, in obese children and adults this prevalence may raise up to 20–80% (Alisi et al., 2009; Vernon et al., 2011).

The term of NAFLD defines a series of hepatic pathologies that include the relatively benign steatosis that may, under the pressure of multiple triggering factors, progress to the more severe condition of non-alcoholic steatohepatitis (NASH), characterized by steatosis, necro-inflammation, and eventually fibrosis (Brunt, 2010).

The NAFLD development is still unclear, however, it is now largely accepted that, beside to the genetic background, the increased consumption of obesogenic foods may have a role in the NAFLD pathogenesis. In particular, diets enriched in fat and fructose may be steatogenic in two ways: favoring the occurrence of systemic insulin resistance closed to a dangerous accumulation of free fatty acid (FFA) in the liver; causing deposition of visceral fat and consequent hepatic insulin resistance responsible for steatosis development (Tilg and Moschen, 2008). Steatotic liver is susceptible to the action of next insults that may exacerbate steatosis and promote NASH. These NASH promoters include: imbalance of production/release of hormones derived from adipose tissue (adipocytokines) with consequent necro-inflammation, oxidative stress, activation of specific nuclear receptors activation, and fibrogenesis (Malaguarnera et al., 2009). In response to the systemic insulin resistance, pancreatic β-cells increase insulin hypersecretion accelerating liver fat accumulation and leading to NAFLD. Recently, it has been reported that also gut-liver axis may play a crucial role in this complex network of multiple interactions (Musso et al., 2010a). In fact, it has been suggested that the diet-dependent increase of gut microbiota products may influence intestinal permeability and activate molecular mechanisms of innate immune response, acting as possible inducer of necro-inflammatory lesions and severe fibrosis in NAFLD (Compare et al., 2012).

The gut microbiota having an extensive cross-talk with the liver represents an important source of hepatotoxic factors comprising bacteria and bacterial products. In such as scenario the intestinal microbiota composition can be affected and dynamically altered by diet regimen, lifestyle, genetic background, antibiotic usage, etc (Compare et al., 2012). The gut microbiota exerts various central functions, among which fermentation of dietary components eluding the digestion and protection against possible invading pathogens (Othman et al., 2008; Cani and Delzenne, 2009). Therefore, the maintenance of the integrity of the intestinal barrier is of crucial importance to preserve an healthy gut-liver axis. In fact, a derangement of the homeostasis between bacteria and host and a qualitative and quantitative alteration of gut flora lead to an increased intestinal permeability. This promotes bacterial and endotoxin translocation triggering a production of pro-inflammatory molecules and cytokines and metabolic disorders. Notably, the intestinal flora, comprised small intestinal overgrowth (SIBO), has been found altered in many chronic liver diseases. On this regard it has been shown that NAFLD patients have an increased intestinal permeability and SIBO (Miele et al., 2009). Several lines of evidence have shown that NAFLD can be affected in different way by gut microbiota. From a side, the microbiota can directly affect the quantity of calories recovered from intestinal contents influencing the body weight possibly preceding the obesity occurrence. Further, gut microbiota and related endotoxemia can be implicated in the development of insulin resistance involved in NAFLD pathogenesis by various mechanisms (Cani et al., 2007a,b; Musso et al., 2010b). Also, the intestinal integrity can be lost by the alteration of the tight junctions causing an increase intestinal permeability which leads to bacterial translocation and their products into the systemic circulation, which in turn reach the liver being correlated to NAFLD (Miele et al., 2009; De Gottardi and McCoy, 2011). The gut liver-axis is the way by which the bacteria and their potential hepatotoxic products (LPS, DNA, RNA, etc.) can easily reach the liver. These microbial compounds can be generally classified as pathogen-associated molecular patterns (PAMPs) while the endogenous products are distinguished...
in damage-associated molecular patterns (DAMPs). Interestingly, the serum levels of lipopolysaccharide (LPS), one of most studied PAMPs, are up-regulated in NASH patients with necro-inflammation and severe liver damage (Alisi et al., 2010). The final effect is the activation of the signaling cascade triggered by specific immune receptor resulting in the expression of pro-inflammatory cytokine genes including tumor necrosis factor (TNF) α and several interleukins (ILs) that may exacerbate hepatocyte damage (Figure 1).

The immune system has generated, along the evolution, a series of specific pattern recognition receptors (PRRs) comprising the Toll-like receptors (TLRs), which are evolutionary conserved type I transmembrane glycoproteins. The TLRs are the immune sensors of PAMPs and/or DAMPs initiating a signaling cascade leading to the activation of pro-inflammatory genes. Notably, each TLR has selectivity for specific PAMPs or DAMPs and can also differ from their proper localization (Alisi et al., 2011). In the liver, TLRs are expressed in many different cell types including Kupffer cells, hepatocytes, and HSCs (Schwabe et al., 2006) being the TLR4 the specific receptor for the bacterial endotoxin LPS, which is the key inducer of pro-inflammatory cytokines (as TNFα, IL-6, IL-8, IL-12, etc.) through the activation of the transcription factors NF-kB (nuclear factor kappa B), AP-1 (activating protein 1) and also LITAF (LPS-induced TNFα factor) in the liver (Alisi et al., 2011).

The gut colonization initiates at birth establishing a dynamic repertoire of gut microbiota during life that can be altered in several way giving rise to different inflammatory conditions possibly leading to more severe disturbances such as NAFLD. Many effort have been made to characterize which bacterial composition is more healthy to preserve the host from metabolic disorders and many progresses have been obtained in animal model on the study of the role of gut microbiota and accumulating evidence from human studies are available, although the examination along the time of the gastrointestinal bacteria composition is more difficult to assess. It has been extensively demonstrated that the proportion of intestinal microbiota is dependent on diet regimen. Interestingly, both in obese human and in mice the amount of the phyla Bacteroidetes and Firmicutes, which represent more than 90% of the totality of the gut microbiota, are altered (the first decreased and the second increased) (Eckburg et al., 2005). It has also been shown that a different balance of Bifidobacterium spp. and faecal Staphylococcus aureus results from the comparison between normal weight children and children which, at long last, can develop into overweight or obese subjects, suggesting a possible preceding condition that can foretell the future obesity occurrence (Kalliomäki et al., 2008). Further, the fat consumption can produce a wide amount of lipoprotein-containing chylomicrons which can guide the translocation of LPS toward other organs comprised the liver (Vreugdenhil et al., 2003). Interestingly, in a study in human choline-depleted diet it was described a correlation among the balance of Gammaproteobacteria/Erysipelotrichi classes and the occurrence of fatty liver (Spencer et al., 2011). Besides, in a murine models fed high-fat diet, the Bifidobacterium spp. administration determined an amelioration of the metabolic panel and a decrease of pro-inflammatory products into the systemic circulation. PAMPs and DAMPs may reach liver cells promoting firstly fat accumulation in hepatocytes and secondly fibrosis and liver cell damage.

**FIGURE 1 | Gut-derived product effects on liver cells during NAFLD development.** Diets enriched in fat and fructose may disrupt intestinal barrier, increase intestinal permeability to gut-derived products, and release of PAMPs and DAMPs into the systemic circulation. PAMPs and DAMPs may reach liver cells promoting firstly fat accumulation in hepatocytes and secondly fibrosis and liver cell damage.
were augmented in parallel with LPS cytokines. Interestingly, the cytokine levels were suppressed over recent years in the attempt of modifying one or more of the major factors involved in NAFLD pathogenesis. Therefore, modifications of gut microbiota may be one of the possible objectives of an efficient multi-target therapy. This option is supported by several investigations in animal models studies suggesting that gut microbiota manipulation with probiotics reduces intestinal inflammation and improves the epithelial barrier function (Iacono et al., 2011). Furthermore, Loguerchio et al. (2005) demonstrated that a chronic therapy with a probiotic (VSL#3) in patients affected by several types of chronic liver diseases, including NAFLD may reduce liver damage and improve serum levels of various biomarkers. Interestingly, a pilot study, involving 20 obese children with hypertransaminasemia and bright liver at ultrasound, found that 8 weeks of treatment with probiotic Lactobacillus rhamnosus strain GG reduced transaminase levels and antipeptidoglycan-polysaccharide antibodies, a surrogate test for SIBO evaluation (Vajro et al., 2011).

In conclusion, as several observations suggest a potential role of microbiota in NAFLD development, we believe that probiotics effects on gut flora associated to NAFLD may reduce liver damage and improve serum levels of various biomarkers. Interestingly, a pilot study, involving 20 obese children with hypertransaminasemia and bright liver at ultrasound, found that 8 weeks of treatment with probiotic Lactobacillus rhamnosus strain GG reduced transaminase levels and antipeptidoglycan-polysaccharide antibodies, a surrogate test for SIBO evaluation (Vajro et al., 2011).

REFERENCES
Alisi, A., Carsetti, R., and Nobili, V. (2011). Pathogenesis of fatty liver disease associated with the gut microbiota in children with obesity. Hepatology 54, 1500–1502.
Alisi, A., Manco, M., Devito, R., Piemonte, F., and Nobili, V. (2010). Endotoxin and plasmogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 50, 645–649.
Alisi, A., Manco, M., Vania, A., and Nobili, V. (2009). Pediatric nonalcoholic fatty liver disease in 2009. J. Pediatr. 155, 469–474.
Alisi, A., and Nobili, V. (2011). Nonalcoholic fatty liver disease: targeted therapy in children—what is the right way? Nat. Rev. Gastroenterol. Hepatol. 8, 425–426.
Brunn, E. M. (2010). Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 7, 195–203.
Cani, P. D., Arman, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., et al. (2007a). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772.
Cani, P. D., Neyrinck, A. M., Fava, F., Knauf, C., Burcelin, R. G., Tuohy, K. M., et al. (2007b). Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxemia. Diabetesologia 50, 2374–2383.
Cani, P. D., and Delzenne, N. M. (2009). The role of the gut microbiota in energy metabolism and metabolic disease. Curr. Pharm. Des. 15, 1546–1558.
Clemente, J. C., Ursell, L. K., Parfrey, L. W., and Knight, R. (2012). The impact of the gut microbiota on human health: an integrative view. Cell 148, 1258–1270.
Compare, D., Coccoli, P., Rocco, A., Nardone, O. M., De Maria, S., Carteni, M., et al. (2012). Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nat. Metab. Cardiovasc. Dis. 22, 471–476.
De Gortari, A., and McCoy, K. D. (2011). Evaluation of the gut barrier to bacterial infection in non-alcoholic fatty liver disease. J. Hepatol. 55, 1391–1399.
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., et al. (2005). Diversity of the human intestinal microbial flora. Science 308, 1635–1638.
Iacono, A., Raso, G. M., Canani, R. B., Calignano, A., and Meli, R. (2011). Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J. Nutr. Biochem. 22, 699–711.
Kalliomäki, M., Collado, M. C., Salminen, S., and Isolauri, E. (2008). Early differences in fecal microflora composition in children may predict overweight. Am. J. Clin. Nutr. 87, 534–538.
Larkin, T. A., Ashteymer, L. B., and Price, W. E. (2009). Dietary combination of soy with a probiotic or prebiotic food significantly reduces total and LDL cholesterol in mildly hypercholesterolemic subjects. Eur. J. Clin. Nutr. 63, 238–245.
Loguerchio, C., Federico, A., Tuccillo, C., Terracciano, E., D’Auria, M. V., De Simone, C., et al. (2005). Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol. 39, 540–543.
Malaguarnera, M., Di Rosa, M., Nicolletti, F., and Malaguarnera, L. (2009). Molecular mechanisms involved in NAFLD progression. J. Mol. Med. 87, 679–695.
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., et al. (2009). Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877–1887.
Milic, S., and Stimac, D. (2012). Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig. Dis. 30, 158–162.
Musso, G., Gambino, R., and Cassader, M. (2010a). Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr. Opin. Lipidol. 21, 76–83.
Musso, G., Gambino, R., and Cassader, M. (2010b). Obesity, diabetes and gut microbiota: the...
hygiene hypothesis expanded? Diabetes Care 33, 2277–2284.
Othman, M., Agüero, R., and Lin, H. C. (2008). Alterations in intestinal microbial flora and human disease. Curr. Opin. Gastroenterol. 24, 11–16.
Schwabe, R. F., Seki, E., and Brenner, D. A. (2006). Toll-like receptor signalling in the liver. Gastroenterology 130, 1886–1900.
Spencer, M. D., Hamp, T. J., Reid, R. W., Fischer, L. M., Zeisel, S. H., and Fodor, A. A. (2011). Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140, 976–986.
Tannock, G. W. (2004). A special fondness for lactobacilli. Appl. Environ. Microbiol. 70, 3189–3194.
Tilg, H., and Moschen, A. R. (2008). Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol. Metab. 19, 371–379.
Vajro, P., Mandato, C., Licenziati, M. R., Franzese, A., Vitale, D. F., Lenta, S., et al. (2011). Effects of Lactobacillus rhamnosus strain GG in pedi atric obesity-related liver disease. J. Pediatr. Gastroenterol. Nutr. 52, 740–743.
Vanni, E., Bugianesi, E., Kotronen, A., De Minicis, S., Yki-Järvinen, H., and Svegliati-Baroni, G. (2010). From the metabolic syndrome to NAFLD or vice versa? Dig. Liver Dis. 42, 320–330.
Vernon, G., Baranova, A., and Younossi, Z. M. (2011). Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274–285.
Veugdenhil, A. C., Rousseau, C. H., Hartung, T., Greve, J. W., van ’t Veer, C., and Buurman, W. A. (2003). Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J. Immunol. 170, 1399–1405.
Xiao, J. Z., Kondo, S., Takahashi, N., Miyagi, K., Oshida, K., Hiramatsu, A., et al. (2003). Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J. Dairy Sci. 86, 2452–2461.

Received: 17 July 2012; accepted: 07 October 2012; published online: 26 October 2012.
Citation: Alisi A, Ceccarelli S, Panera N and Nobili V (2012) Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front. Cell. Inf. Microbiol. 2:132. doi:10.3389/fcimb.2012.00132
Copyright © 2012 Alisi, Ceccarelli, Panera and Nobili. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.